Mark A. Wainberg, Ph.D.
Dr. Wainberg is Director of the McGill University AIDS Centre and Professor of Medicine and of Microbiology at McGill University in Montreal, Canada. He is an internationally recognized HIV scientist, and has made significant independent contributions to the study of antiviral drug development and HIV drug resistance. He served as President of the International AIDS Society from 1998-2000.
Among Dr. Wainberg's most notable achievements is his initial identification (in collaboration with BioChem Pharma) of the antiviral capabilities of 3TC in 1989. His laboratory continues to work in similar areas, and Dr. Wainberg has also turned his attention to investigating novel concepts in the development of an HIV vaccine and other modes of HIV prevention. He is a strong advocate of measures that will enhance prevention of HIV infection in developing countries.
Dr. Wainberg was the Chair of the XVI International AIDS Conference, which took place in Toronto during the summer of 2006. Dr. Wainberg is a member of the Royal Society of Canada and an Officer of the Order of Canada. He currently resides in Montreal with his wife; the couple has two children.
Dr. Wainberg has been a consultant for Boehringer Ingelheim, Abbott Laboratories and GlaxoSmithKline. He has received research support from Gilead Sciences, Merck & Co. and GlaxoSmithKline and has served on speakers bureaus for Abbott and Boehringer Ingelheim.